466 related articles for article (PubMed ID: 21362516)
21. Targeting personalized medicine in a non-Hodgkin lymphoma patient with 18F-FDG and 18F-choline PET/CT.
Ribeiro TH; S R; Castro AC; Paulino E; Mamede M
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):109-111. PubMed ID: 28355370
[TBL] [Abstract][Full Text] [Related]
22. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
23. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
[TBL] [Abstract][Full Text] [Related]
24. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.
Shen B; Huang T; Sun Y; Jin Z; Li XF
Oncotarget; 2017 Jun; 8(26):43536-43542. PubMed ID: 28402949
[TBL] [Abstract][Full Text] [Related]
25. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
26. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
27. FDG PET Hybrid Imaging.
Becker J; Schwarzenböck SM; Krause BJ
Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
[TBL] [Abstract][Full Text] [Related]
28. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography imaging in evaluation of cancer patients.
Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives.
Wu D; Gambhir SS
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S55-63. PubMed ID: 12756080
[TBL] [Abstract][Full Text] [Related]
31. Metabolic PET Imaging in Oncology.
Sai KKS; Zachar Z; Bingham PM; Mintz A
AJR Am J Roentgenol; 2017 Aug; 209(2):270-276. PubMed ID: 28463521
[TBL] [Abstract][Full Text] [Related]
32. Clinical applications of positron emission tomography-computed tomography in oncology.
Kumar R; Halanaik D; Malhotra A
Indian J Cancer; 2010; 47(2):100-19. PubMed ID: 20448371
[TBL] [Abstract][Full Text] [Related]
33. Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist.
Beadsmoore C; Newman D; MacIver D; Pawaroo D
Can Assoc Radiol J; 2015 Nov; 66(4):332-47. PubMed ID: 26277234
[TBL] [Abstract][Full Text] [Related]
34. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
35. Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Tseng JC; Narayanan N; Ho G; Groves K; Delaney J; Bao B; Zhang J; Morin J; Kossodo S; Rajopadhye M; Peterson JD
PLoS One; 2017; 12(8):e0182689. PubMed ID: 28792505
[TBL] [Abstract][Full Text] [Related]
36. State-of-the-Art FDG-PET imaging of lung cancer.
Gilman MD; Aquino SL
Semin Roentgenol; 2005 Apr; 40(2):143-53. PubMed ID: 15898411
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study.
Tian M; Zhang H; Endo K
J Biomed Biotechnol; 2011; 2011():807929. PubMed ID: 21738405
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
39. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDG PET/CT.
Wu HB; Wang QS; Wang MF; Zhen X; Zhou WL; Li HS
J Nucl Med; 2011 Mar; 52(3):341-6. PubMed ID: 21321282
[TBL] [Abstract][Full Text] [Related]
40. Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI.
Theruvath AJ; Siedek F; Muehe AM; Garcia-Diaz J; Kirchner J; Martin O; Link MP; Spunt S; Pribnow A; Rosenberg J; Herrmann K; Gatidis S; Schäfer JF; Moseley M; Umutlu L; Daldrup-Link HE
Radiology; 2020 Jul; 296(1):143-151. PubMed ID: 32368961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]